Standard Biotools is trading 5.36% higher at $0.67 on October 15, 2026, with no clear catalyst identified. - No new company-specific announcement or reliable report tied the move directly to a catalyst today. - The announced Microfluidics sale to ARCHIMED and revised Mass Cytometry sale agreement predate this session. - Healthcare sector strength may offer support, but reporting linked the rally to large healthcare companies’ earnings, not a Standard Biotools-specific development.